{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:09:36Z","timestamp":1781276976987,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,20]]},"DOI":"10.7759\/cureus.82650","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T02:50:41Z","timestamp":1745203841000},"source":"Crossref","is-referenced-by-count":2,"title":["Aggressive and Refractory Attack of AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder Treated With Ravulizumab: A Case Report"],"prefix":"10.7759","author":[{"given":"Jos\u00e9 M","family":"Vald\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Orellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianella","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Barahona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Galleguillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel T","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, et al.. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the neuromyelitis optica Study Group (NEMOS). Part II: attack therapy and long-term management. J Neurol. 2024, 271:141-76. 10.1007\/s00415-023-11910-z","journal-title":"J Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock SJ","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, et al.. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023, 93:1053-68. 10.1002\/ana.26626","journal-title":"Ann Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106244","article-title":"Recommendations on NMOSD treatment in Latin America: utilizing consensus-based RAND\/UCLA methodology","volume":"94","author":"Alonso R","year":"2025","unstructured":"Alonso R, Rivera V, Carnero Contentti EG, et al.. Recommendations on NMOSD treatment in Latin America: utilizing consensus-based RAND\/UCLA methodology. Mult Scler Relat Disord. 2025, 94:106244. 10.1016\/j.msard.2024.106244","journal-title":"Mult Scler Relat Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1332890","article-title":"Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"15","author":"Ortiz S","year":"2024","unstructured":"Ortiz S, Pittock SJ, Berthele A, et al.. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Front Neurol. 2024, 15:1332890. 10.3389\/fneur.2024.1332890","journal-title":"Front Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu T","year":"2023","unstructured":"Vu T, Ortiz S, Katsuno M, et al.. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J Neurol. 2023, 270:3129-37. 10.1007\/s00415-023-11617-1","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1303874","article-title":"Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study","volume":"14","author":"Marignier R","year":"2023","unstructured":"Marignier R, Laplaud D, Z\u00e9phir H, et al.. Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study. Front Neurol. 2023, 14:1303874. 10.3389\/fneur.2023.1303874","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.951423","article-title":"Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report","volume":"13","author":"Chatterton S","year":"2022","unstructured":"Chatterton S, Parratt JD, Ng K. Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report. Front Neurol. 2022, 13:951423. 10.3389\/fneur.2022.951423","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06971-x","article-title":"Eculizumab for a catastrophic relapse in NMOSD: case report","volume":"45","author":"Gorriz D","year":"2024","unstructured":"Gorriz D, P\u00e9rez-Miralles FC, Quintanilla-Bord\u00e1s C, Alcal\u00e1 C, Frasquet M, Casanova B. Eculizumab for a catastrophic relapse in NMOSD: case report. Neurol Sci. 2024, 45:249-51. 10.1007\/s10072-023-06971-x","journal-title":"Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16490","article-title":"Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"31","author":"Habib AA","year":"2024","unstructured":"Habib AA, Benatar M, Vu T, et al.. Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Eur J Neurol. 2024, 31:e16490. 10.1111\/ene.16490","journal-title":"Eur J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12234-2","article-title":"Ravulizumab in myasthenic crisis: the first case report","volume":"271","author":"Konen FF","year":"2024","unstructured":"Konen FF, Jendretzky KF, Ratuszny D, et al.. Ravulizumab in myasthenic crisis: the first case report. J Neurol. 2024, 271:2898-901. 10.1007\/s00415-024-12234-2","journal-title":"J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis","volume":"268","author":"Siritho S","year":"2021","unstructured":"Siritho S, Nopsopon T, Pongpirul K. Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. J Neurol. 2021, 268:4549-62. 10.1007\/s00415-020-10257-z","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00597-7","article-title":"Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder","volume":"13","author":"Clardy SL","year":"2024","unstructured":"Clardy SL, Pittock SJ, Aktas O, et al.. Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder. Neurol Ther. 2024, 13:535-49. 10.1007\/s40120-024-00597-7","journal-title":"Neurol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105524","article-title":"Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: a systematic review and meta-analysis","volume":"85","author":"Makkawi S","year":"2024","unstructured":"Makkawi S, Salamatullah HK, Alkhiri A, et al.. Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: a systematic review and meta-analysis. Mult Scler Relat Disord. 2024, 85:105524. 10.1016\/j.msard.2024.105524","journal-title":"Mult Scler Relat Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00932","article-title":"Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD","volume":"11","author":"Akaishi T","year":"2020","unstructured":"Akaishi T, Takeshita T, Himori N, et al.. Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD. Front Neurol. 2020, 11:932. 10.3389\/fneur.2020.00932","journal-title":"Front Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish H","year":"2019","unstructured":"Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, Lotan I. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?. Neurol Neuroimmunol Neuroinflamm. 2019, 6:e572. 10.1212\/NXI.0000000000000572","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan M","year":"2018","unstructured":"Bonnan M, Valentino R, Debeugny S, Merle H, Ferg\u00e9 JL, Mehdaoui H, Cabre P. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018, 89:346-51. 10.1136\/jnnp-2017-316286","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-025-02238-9","article-title":"Longitudinal improvement in respiratory function following plasma exchange in patients with severe myasthenia gravis","author":"Varelas PN","year":"2025","unstructured":"Varelas PN, Lopez-Plaza I, Ata A, Rehman MF, Mehta C, Ramadan R, Zisimopoulou V. Longitudinal improvement in respiratory function following plasma exchange in patients with severe myasthenia gravis. Neurocrit Care. 2025, 10.1007\/s12028-025-02238-9","journal-title":"Neurocrit Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting eculizumab as rescue therapy in refractory myasthenic crisis","volume":"44","author":"Vinciguerra C","year":"2023","unstructured":"Vinciguerra C, Bevilacqua L, Toriello A, Iovino A, Piscosquito G, Calicchio G, Barone P. Starting eculizumab as rescue therapy in refractory myasthenic crisis. Neurol Sci. 2023, 44:3707-9. 10.1007\/s10072-023-06900-y","journal-title":"Neurol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8090355","article-title":"The inhibition of complement system in formal and emerging indications: results from parallel one-stage pairwise and network meta-analyses of clinical trials and real-life data studies","volume":"8","author":"Bernuy-Guevara C","year":"2020","unstructured":"Bernuy-Guevara C, Chehade H, Muller YD, et al.. The inhibition of complement system in formal and emerging indications: results from parallel one-stage pairwise and network meta-analyses of clinical trials and real-life data studies. Biomedicines. 2020, 8:355. 10.3390\/biomedicines8090355","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/360166-aggressive-and-refractory-attack-of-aqp4-igg-positive-neuromyelitis-optica-spectrum-disorder-treated-with-ravulizumab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T02:50:42Z","timestamp":1745203842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/360166-aggressive-and-refractory-attack-of-aqp4-igg-positive-neuromyelitis-optica-spectrum-disorder-treated-with-ravulizumab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.82650","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,20]]}}}